ALNY
Price
$445.12
Change
+$15.32 (+3.56%)
Updated
Nov 26 closing price
Capitalization
58.81B
77 days until earnings call
Intraday BUY SELL Signals
BEAM
Price
$25.03
Change
+$0.34 (+1.38%)
Updated
Nov 26 closing price
Capitalization
2.54B
96 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALNY vs BEAM

Header iconALNY vs BEAM Comparison
Open Charts ALNY vs BEAMBanner chart's image
Alnylam Pharmaceuticals
Price$445.12
Change+$15.32 (+3.56%)
Volume$908.16K
Capitalization58.81B
Beam Therapeutics
Price$25.03
Change+$0.34 (+1.38%)
Volume$1.37M
Capitalization2.54B
ALNY vs BEAM Comparison Chart in %
ALNY
Daily Signal:
Gain/Loss:
BEAM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ALNY vs. BEAM commentary
Nov 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a StrongBuy and BEAM is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 27, 2025
Stock price -- (ALNY: $445.12 vs. BEAM: $25.03)
Brand notoriety: ALNY and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 85% vs. BEAM: 58%
Market capitalization -- ALNY: $58.81B vs. BEAM: $2.54B
ALNY [@Biotechnology] is valued at $58.81B. BEAM’s [@Biotechnology] market capitalization is $2.54B. The market cap for tickers in the [@Biotechnology] industry ranges from $109.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 2 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).

  • ALNY’s FA Score: 2 green, 3 red.
  • BEAM’s FA Score: 1 green, 4 red.
According to our system of comparison, ALNY is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 5 TA indicator(s) are bullish while BEAM’s TA Score has 4 bullish TA indicator(s).

  • ALNY’s TA Score: 5 bullish, 5 bearish.
  • BEAM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALNY is a better buy in the short-term than BEAM.

Price Growth

ALNY (@Biotechnology) experienced а -3.39% price change this week, while BEAM (@Biotechnology) price change was +19.30% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -1.24%, and the average quarterly price growth was +71.95%.

Reported Earning Dates

ALNY is expected to report earnings on Feb 12, 2026.

BEAM is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($58.8B) has a higher market cap than BEAM($2.54B). ALNY YTD gains are higher at: 89.163 vs. BEAM (0.927). ALNY has higher annual earnings (EBITDA): 187M vs. BEAM (-414.33M). ALNY has more cash in the bank: 2.73B vs. BEAM (1.15B). BEAM has less debt than ALNY: BEAM (155M) vs ALNY (1.31B). ALNY has higher revenues than BEAM: ALNY (3.21B) vs BEAM (60.3M).
ALNYBEAMALNY / BEAM
Capitalization58.8B2.54B2,315%
EBITDA187M-414.33M-45%
Gain YTD89.1630.9279,614%
P/E Ratio1483.73N/A-
Revenue3.21B60.3M5,323%
Total Cash2.73B1.15B237%
Total Debt1.31B155M844%
FUNDAMENTALS RATINGS
ALNY vs BEAM: Fundamental Ratings
ALNY
BEAM
OUTLOOK RATING
1..100
678
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
9100
SMR RATING
1..100
2894
PRICE GROWTH RATING
1..100
4443
P/E GROWTH RATING
1..100
44100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BEAM's Valuation (30) in the null industry is significantly better than the same rating for ALNY (100) in the Biotechnology industry. This means that BEAM’s stock grew significantly faster than ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (9) in the Biotechnology industry is significantly better than the same rating for BEAM (100) in the null industry. This means that ALNY’s stock grew significantly faster than BEAM’s over the last 12 months.

ALNY's SMR Rating (28) in the Biotechnology industry is significantly better than the same rating for BEAM (94) in the null industry. This means that ALNY’s stock grew significantly faster than BEAM’s over the last 12 months.

BEAM's Price Growth Rating (43) in the null industry is in the same range as ALNY (44) in the Biotechnology industry. This means that BEAM’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's P/E Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that ALNY’s stock grew somewhat faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYBEAM
RSI
ODDS (%)
Bullish Trend 1 day ago
83%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
66%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
89%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
63%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 1 day ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
64%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signal:
Gain/Loss:
BEAM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
COSNX13.270.17
+1.30%
Columbia Overseas Core Institutional
PPSRX20.89N/A
N/A
Principal Large Cap Value III R5
JDVFX25.74N/A
N/A
JHancock Disciplined Value R4
SLARX36.67N/A
N/A
DWS Latin America Equity Inst
ZVGNX56.47N/A
N/A
Zevenbergen Genea Investor

ALNY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALNY has been loosely correlated with ARGX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ALNY jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALNY
1D Price
Change %
ALNY100%
+3.56%
ARGX - ALNY
47%
Loosely correlated
+0.01%
IONS - ALNY
45%
Loosely correlated
+2.19%
SGMO - ALNY
42%
Loosely correlated
+11.78%
AXSM - ALNY
38%
Loosely correlated
+0.41%
BBIO - ALNY
37%
Loosely correlated
+1.54%
More